TORONTO, June 06, 2025 (GLOBE NEWSWIRE) -- BE Resources Inc. (TSX-V: BER.H) (“BE Resources” or the “Company”) announces that, further to the Company’s press release dated March 6, 2025, the Company settled C$361,361.23 of debt owed to certain creditors of the Company in consideration for the issuance of 5,559,399 common shares of the Company (the “Shares”) at a deemed price of C$0.065 per Share (the “Debt Settlement”). The Company expects that the proposed Debt Settlement will assist the Company in preservi ...

MIAMI, June 06, 2025 (GLOBE NEWSWIRE) -- AYR Wellness Inc. (CSE: AYR.A, OTCQX: AYRWF) (“AYR” or the “Company”), a leading vertically integrated U.S. multi-state cannabis operator, today provides an update regarding the status of its securities in connection with its previously announced delay in filing its interim financial statements for the quarter ended March 31, 2025.‎ As disclosed on May 30, 2025, the Company was unable to meet the deadline to file its interim financial report, management’s discussion ...

Core Insights - ProPhase Labs Inc. has established a Clinical Science Advisory Board to facilitate the clinical adoption and commercialization of its BE-Smart molecular test for esophageal disease, aiming to set a new standard in early detection and management of esophageal cancer risk [1][10] - The BE-Smart test is positioned to capture a target market of approximately $7 - $14 billion, based on the 7 million endoscopies performed annually in the U.S. for patients at risk of esophageal cancer, with a reimbursement goal of $1,000 - $2,000 per test [3] Company Overview - ProPhase Labs Inc. is a next-generation biotech, genomics, and consumer products company focused on innovative healthcare solutions, including Whole Genome Sequencing and diagnostic developments [11] - The company aims to revolutionize healthcare through actionable insights and is committed to executional excellence and smart diversification [11] Advisory Board Composition - The advisory board includes Dr. Joe Abdo, the inventor of the BE-Smart test, and Mr. James McCullough, founder and CEO of Renalytix, both of whom bring extensive experience in molecular oncology and diagnostic technologies [2][9] - Additional experts will be added to the advisory board to support the initial commercial launch of BE-Smart [2] Product Features and Advantages - BE-Smart offers a unique approach by measuring real-time protein activity, which captures dynamic biological signals of disease progression, requiring only a single 10 µm FFPE biopsy section [3][4] - The test integrates into existing endoscopy and pathology workflows, providing results in under 7 days without added complexity for healthcare providers [3] Clinical Utility - BE-Smart can stratify risk for patients with GERD and Barrett's Esophagus, addressing limitations of current diagnostic tools [4] - The test's design is scalable and cost-efficient, making it an attractive option for clinicians and healthcare systems [4] Competitive Landscape - Other technologies like TissueCypher and EsoGuard have established momentum in esophageal diagnostics, paving the way for broader adoption of molecular tools [5] - BE-Smart builds on this progress by offering a next-generation approach that combines real-time biological precision with streamlined clinical integration [5] Intellectual Property - ProPhase Labs has secured exclusive patents covering proprietary methods for detecting and analyzing eight key proteins critical for esophageal adenocarcinoma progression, providing a competitive advantage in the molecular diagnostics market [6] Clinical Validation - The latest clinical validation manuscript for BE-Smart is under review at the Journal of Clinical Gastroenterology and Hepatology, with a preprint expected soon [7][8]

Company Overview - Neo Performance Materials Inc. is a manufacturer of advanced industrial materials that enhance efficiency and sustainability, including magnetic powders, rare earth magnets, and specialty chemicals [5] - The company operates in three segments: Magnequench, Chemicals & Oxides, and Rare Metals, with a global presence including manufacturing facilities in China, Germany, Canada, Estonia, Thailand, and the UK, as well as a dedicated R&D center in Singapore [5] Market Transition - Neo Performance Materials has upgraded to trade on the OTCQX Best Market from the Pink market, which is a significant step for enhancing transparency and accessibility for U.S. investors [1][3] - The company will begin trading under the symbol "NOPMF" on the OTCQX, allowing U.S. investors to access real-time financial disclosures [2] Strategic Positioning - The CEO of Neo Performance Materials emphasized that the upgrade to OTCQX enhances the company's visibility and accessibility for U.S. investors, positioning it well to meet the growing demand for critical materials in electrification and modern technologies [4] - The company aims to broaden its shareholder base while executing its strategic priorities to drive long-term value [4]

Core Viewpoint - Nurix Therapeutics is set to present new data from the ongoing Phase 1 clinical trial of bexobrutideg (NX-5948) at the European Hematology Association Congress, highlighting the company's focus on targeted protein degradation medicines for cancer treatment [1][5]. Company Overview - Nurix Therapeutics is a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of targeted protein degradation medicines aimed at improving treatment options for cancer and inflammatory diseases [5]. - The company's pipeline includes degraders of Bruton's tyrosine kinase (BTK) and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), with a focus on innovative drug design [5]. - Nurix is advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline, supported by a fully AI-integrated discovery engine [5]. Clinical Trial Information - Bexobrutideg (NX-5948) is an investigational, orally bioavailable small molecule degrader of BTK, currently evaluated in a Phase 1 clinical trial for patients with relapsed or refractory B cell malignancies [4]. - The ongoing clinical trial can be accessed for additional information at clinicaltrials.gov (NCT05131022) [4]. Upcoming Presentations - The company will host a webcast conference call on June 12, 2025, to discuss the new data from the Phase 1 clinical trial, which will be presented at the EHA2025 [1][2]. - Presentations at EHA2025 include findings on the clinical activity and safety of bexobrutideg in patients with chronic lymphocytic leukemia (CLL) and Waldenström macroglobulinemia, scheduled for June 13 and June 14, respectively [6].

Core Insights - HydroGraph Clean Power Inc. has appointed two new independent directors, Tom Wilkinson and Grant Duthie, to strengthen its board as the company transitions to commercial operations [1][2][3] Group 1: Board Appointments - The new directors bring extensive experience in operations, strategy, leadership, audit, governance, and public company management, aligning with the company's focus on innovation and growth [2][3] - The appointments fill vacancies left by the resignations of Paul Cox and David Williams, who left to pursue other business interests [5] Group 2: Company Transition - HydroGraph is moving from a development stage to commercial operations, with a growing pipeline of prospective customers for its graphene products across various end markets [3][4] - The company aims to secure its first commercial customers and build a scalable high-volume manufacturing facility to establish itself as a global leader in the graphene industry [4] Group 3: New Directors' Background - Tom Wilkinson has over thirty years of experience as a business leader and advisor, previously serving as CFO for Amelia Holdings and CEO for multiple technology companies [6][7] - Grant Duthie is a partner at Garfinkle & Biderman, focusing on securities, corporate finance, and M&A, with experience in advising various industry sectors [9][10]

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, June 06, 2025 (GLOBE NEWSWIRE) -- Fury Gold Mines Limited (TSX and NYSE American: FURY) (“Fury” or the “Company”) announces that the proposed private placement offering announced June 5, 2025 has been increased from C$2,500,000 to C$3,080,000. Fury now intends to privately place with a small group of accredited and institutional investors in Canada a total of 4,000,000 flow-through common shares (the “ ...

VANCOUVER, BC, June 06, 2025 (GLOBE NEWSWIRE) -- Eat & Beyond Global Holdings Inc. (CSE: EATS) (OTCPK: EATBF) (FSE: 988) (“Eat & Beyond” or the “Company”), is pleased to announce that that globally recognized entrepreneur, investor, and citizen journalist Mario Nawfal has joined the Company as a Strategic Advisor. Mr. Nawfal is a force in modern media and Web3 innovation. As the founder of The Roundtable, X/Twitter’s most influential audio show, he has hosted global icons including Elon Musk, Marc Andreess ...

ORLADEYO® (berotralstat) now reimbursed in the NetherlandsRESEARCH TRIANGLE PARK, N.C., June 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that, following a positive recommendation from the Zorginstituut Nederland, ORLADEYO® (berotralstat) has been approved for the routine prevention of hereditary angioedema (HAE) attacks in patients aged 12 years and older. This reimbursement approval in the Netherlands marks national reimbursement for ORLADEYO across all major ...

SHENZHEN, China, June 06, 2025 (GLOBE NEWSWIRE) -- MoonFox Data, China’s leading provider of all-scenario data insights and analytics services, was recently invited to deliver a keynote address at the Neudata Hong Kong Data Summit 2025, held at the Hong Kong Cordis Hotel. Senior Analyst Max Ma presented "Navigating China's Market Pulse in 2025: Data-Driven Strategic Investment Insights," offering global investment institutions and enterprise clients an in-depth analysis of the latest trends in China's macro ...